Welcome to our dedicated page for Pharmacyte Biotech news (Ticker: PMCB), a resource for investors and traders seeking the latest updates and insights on Pharmacyte Biotech stock.
PharmaCyte Biotech, Inc. reports developments as a biotechnology issuer evaluating its Cell-in-a-Box® live-cell encapsulation technology while deploying capital into external public-company investments. News commonly covers strategic investments and monetizations, financing activity, cash and marketable-securities positioning, and corporate updates on potential development paths for cellular therapies in cancer, diabetes and malignant ascites.
PharmaCyte Biotech (OTCQB: PMCB) is actively addressing a U.S. FDA clinical hold to advance its Phase 2b trial for locally advanced pancreatic cancer (LAPC). Since the clinical hold notification on October 1, 2020, the company has undertaken extensive studies, including product stability tests and biocompatibility assessments. CEO Kenneth L. Waggoner emphasized the length and complexity of the required studies but expressed commitment to resolving FDA concerns. The company's innovative CypCaps therapy aims to target pancreatic cancer effectively, making strides toward resuming clinical trials.
PharmaCyte Biotech (OTCQB: PMCB) announced that a majority of its shareholders voted in favor of increasing the authorized number of shares of common stock, essential for the ongoing development of its pancreatic cancer therapy. The Annual Shareholder Meeting on June 16, 2021, also saw other proposals pass. The official vote results will be disclosed during the reconvened meeting on June 30, 2021. CEO Kenneth L. Waggoner expressed gratitude for shareholder support, emphasizing the importance of Proposal No. 2 for the company’s viability and therapy progress.
PharmaCyte Biotech (OTCQB: PMCB) has announced the adjournment of its 2021 Annual Meeting of Stockholders to June 30, 2021, to allow more time for voting on Proposal No. 2, which seeks to increase the authorized shares of capital stock. CEO Kenneth L. Waggoner emphasized the importance of this proposal for the company's viability and continued development of its pancreatic cancer therapy. Currently, over 49% of shares have voted in favor, but over 50% is needed for approval. The meeting will be held virtually.
PharmaCyte Biotech (OTCQB: PMCB) will hold its Annual Meeting of Shareholders virtually on June 16, 2021, at 11:00 A.M. PDT. Shareholders should have received a Proxy Statement with four proposals to vote on, including a critical one for the development of its pancreatic cancer treatment. CEO Kenneth L. Waggoner emphasized the importance of voting 'yes' for ongoing viability and clinical progress. The meeting will provide updates on addressing FDA requests for the clinical hold on their pancreatic cancer therapy and discuss other company matters.
PharmaCyte Biotech, Inc. (OTCQB: PMCB) announced successful completion of a twelve-month product stability test for its CypCaps™ clinical trial product. This testing is crucial for an upcoming trial targeting locally advanced, inoperable pancreatic cancer, pending FDA approval. CEO Kenneth L. Waggoner highlighted the product's stability at -80°C, which meets all necessary criteria. The ongoing stability study aims to determine the maximum shelf life of CypCaps™. Previous studies indicate that similar products have longer shelf life capabilities, enhancing product viability.
PharmaCyte Biotech (OTCQB: PMCB) has initiated additional studies to determine the DNA sequence of the enzyme in its CypCaps® product for pancreatic cancer, as requested by the FDA. The studies will enhance existing data on the enzyme's stability and configuration, which is essential for its biological activity. CEO Kenneth Waggoner expressed optimism about addressing FDA feedback regarding their treatment for inoperable pancreatic cancer, emphasizing that the product remains functional and effective despite the need for further data validation.
PharmaCyte Biotech (OTCQB: PMCB) has begun additional testing for its CypCaps product targeting pancreatic cancer, following FDA recommendations. The FDA requested two new quality control methods to assess the encapsulated cells' strength, including testing for pressure resistance. Previous studies have indicated that the capsules remain intact under extreme conditions, ensuring patient safety. CEO Kenneth L. Waggoner expressed optimism about addressing FDA concerns to lift the clinical hold on the trial. These developments are crucial for advancing PharmaCyte's innovative cancer treatment.